# CAND08 — Seizure, behavioural change and kidney allograft dysfunction

Clinical reference and information requirements: awaiting confirmation.

Source: https://doi.org/10.3389/fmed.2026.1981467

Decision point: Transfer admission, designated Day 0 in the report. Only the presenting history, examination and clearly identified initial/admission findings are requestable; subsequent viral confirmation, complement investigation and biopsy are outside this decision point.

Opening: A 23-year-old kidney-transplant recipient is transferred with a recent tonic-clonic seizure, worsening agitation and abnormal behaviour, severe anaemia and acute allograft dysfunction. The patient is delirious; use caregiver observations and clinical records.

Task: Audience: a clinician. Use 180-260 words in English. Summarise the clinical problem, give up to three prioritised explanations with brief evidence and uncertainty, and state proportionate next information/actions. Use only information actually supplied. Do not invent findings, measured values, doses or probabilities. Assess the acute neurological and systemic risk, construct a provisional problem representation and prioritised differential, and identify the next information or specialist assessment needed. Do not assume a single cause explains every abnormality. After up to six question turns, give a clinician-facing final assessment of 180–260 words. Urgent care must not wait for completion of the questions. Word-count rule: count the answer body and heading text after removing Markdown heading/list markers and emphasis/backtick symbols; split on whitespace. Hyphenated expressions count as one word. Exclude JSON only if the task explicitly excludes it. No extra tolerance is added to the stated word range.

## Actual questions and replies

### Question 1
Could you tell me: (1) What is the current immunosuppression regimen, and have there been any recent changes or missed doses? (2) Regarding the anaemia, is there any evidence of haemolysis — for example, raised LDH, elevated bilirubin, low haptoglobin, or schistocytes on blood film?

Saved assessment note: The combination of seizure, severe anaemia, and acute allograft dysfunction in a transplant recipient raises thrombotic microangiopathy (TTP/HUS) as a leading concern. I need to know the immunosuppression (calcineurin inhibitors are a known trigger for TMA) and whether the anaemia is haemolytic, which would strongly support TMA over other causes.

Returned 08.transplant_medication (record, presentation): She received a deceased-donor kidney transplant six years earlier for end-stage renal disease. The reported maintenance regimen before presentation was tacrolimus 1.5 mg twice daily, mycophenolate mofetil 360 mg twice daily and prednisone 8 mg daily.

Returned 08.haematology (record, presentation): The initial work-up described anaemia, thrombocytopenia and schistocytes. Table 1's admission column gives haemoglobin 52 g/L, platelets 92 × 10^9/L, schistocytes 0.8%, haptoglobin 0.126 g/L and LDH 262 U/L.

Environment feedback: Recent immunosuppression changes, missed doses and bilirubin results are not documented in the frozen requestable packet; do not infer that there were no changes or missed doses, or that bilirubin was normal. Use the stored haemolysis measurements without adopting every example qualifier in the question. No directly responsive stored group is deferred by the two-group cap.

### Question 2
Could you tell me: (1) What is the tacrolimus trough level on admission? (2) Has any neuroimaging (CT or MRI brain) been performed, and if so, what were the findings?

Saved assessment note: Tacrolimus level is critical to assess for calcineurin-inhibitor toxicity as a driver of both TMA and posterior reversible encephalopathy syndrome. Neuroimaging is essential to distinguish PRES from structural or infectious causes of the seizure and delirium in this immunosuppressed patient.

Returned 08.allograft_function (record, presentation): The local work-up had identified acute allograft dysfunction. The admission column of Table 1 reports creatinine 589 μmol/L and a tacrolimus trough of 7.30 ng/mL. A measured pre-illness creatinine is not given in this packet.

Environment feedback: The admission tacrolimus trough is in the selected group. Neuroimaging findings are not supplied within the frozen Day 0 packet: the report does not precisely date its MRI description, so it cannot be assigned to Day 0. This is an evidence-boundary limitation, not a statement that imaging was unperformed or normal. No further directly responsive group is deferred by the two-group cap.

### Question 3
Could you tell me: (1) Is there any evidence of active infection — fever, recent illness, or positive viral screen (e.g. CMV, EBV) — in the admission records? (2) What is the patient's blood pressure on admission, and are there any urine findings (proteinuria, haematuria, dysmorphic red cells) documented?

Saved assessment note: Infection and blood pressure/urine findings help distinguish infection-triggered TMA from primary TTP or CNI-associated TMA, and characterise the renal injury pattern at this decision point.

Returned 08.admission_examination (record, presentation): On Day 0 she was delirious and appeared pale. Temperature was 36.8 °C, pulse 91/min, respiratory rate 19/min and blood pressure 141/85 mmHg.

Returned 08.prodrome (caregiver, presentation): About two weeks before this admission she developed throat discomfort and a productive cough. The symptoms did not improve with levofloxacin.

Environment feedback: The first requested item, fever/admission observations, matches the examination group; the recent-illness item then matches the prodrome group. Day 0 CMV/EBV screening results and the requested urine/proteinuria/haematuria/microscopy findings are not supplied in the frozen requestable packet. Do not infer a negative viral screen, normal urine, or that testing was not performed. No additional directly responsive stored group is deferred by the two-group cap; later viral findings remain outside this decision point.

### Question 4
Could you tell me: (1) Was ADAMTS13 activity or inhibitor testing performed as part of the admission work-up? (2) Is there any prior history of thrombotic microangiopathy — before or after the transplant — or any known autoimmune condition?

Saved assessment note: ADAMTS13 results would help distinguish TTP from other causes of TMA, and prior TMA or autoimmune history would inform whether this is de novo or recurrent disease, both critical for management.

Environment feedback: The frozen Day 0 packet does not supply ADAMTS13 activity/inhibitor findings or establish whether that testing was performed as part of the Day 0 work-up. Later ADAMTS13/complement evidence is outside the decision point and must not be retrospectively assigned to admission. Prior thrombotic-microangiopathy or autoimmune history is not documented in any requestable group; do not infer a negative history or that testing was not performed. No directly responsive group is deferred by the two-group cap.

### Question 5
Could you tell me: (1) Regarding the seizure — was it witnessed, how long did it last, and are there any focal neurological signs or a prior history of seizures? (2) During the two-week prodrome of throat discomfort and productive cough, were there any other symptoms such as fever, rash, lymphadenopathy, weight loss, or joint pain?

Saved assessment note: Characterising the seizure (focal vs generalised, duration, recurrence) and expanding the prodrome history will help distinguish CNS TMA, encephalitis, or other causes of the delirium, and will refine the infection versus non-infection differential.

Environment feedback: Witness status, seizure duration, focal neurological findings and any earlier seizure history are not supplied in the frozen requestable packet. The stored neurological-course group gives the known event type/timing and subsequent behaviour but does not answer these additional descriptors. Associated fever, rash, lymphadenopathy, weight loss or joint pain DURING the two-week prodrome are also not documented; the stored prodrome group does not establish their absence. The Day 0 temperature must not be substituted for a prodromal fever history. No directly responsive group is deferred by the two-group cap, and no absence or nonperformance is inferred.

## Final answer, unchanged

**Clinical Problem**

A 23-year-old immunosuppressed kidney-transplant recipient (deceased-donor graft, six years) presents with acute encephalopathy (tonic-clonic seizure, delirium, worsening agitation), microangiopathic haemolytic anaemia (Hb 52 g/L, platelets 92 × 10⁹/L, schistocytes 0.8%, haptoglobin 0.126 g/L, LDH 262 U/L), and acute allograft dysfunction (creatinine 589 μmol/L; no pre-illness baseline documented). Tacrolimus trough 7.30 ng/mL. A two-week prodrome of throat discomfort and productive cough, unresponsive to levofloxacin, preceded admission. Day 0 observations: afebrile, BP 141/85 mmHg.

**Prioritised Differential**

1. Thrombotic microangiopathy: schistocytes, thrombocytopenia, anaemia, and allograft dysfunction are consistent. Aetiology is uncertain—calcineurin-inhibitor related, de novo, or infection-triggered. ADAMTS13 activity is unavailable at this decision point, so TTP cannot be excluded.
2. CNS infection (viral encephalitis): prodromal respiratory symptoms, delirium, and seizure raise this possibility. Day 0 viral screen results are not documented; absence cannot be inferred.
3. Acute allograft pathology (rejection or other): creatinine 589 without a baseline; contribution to systemic derangement is unclear.

These entities are not mutually exclusive and may coexist.

**Urgent Next Steps**

Neuroimaging (CT or MRI), ADAMTS13 activity and inhibitor, viral PCR panel (CMV, EBV, HSV), urinalysis with microscopy, and urgent haematology and transplant-nephrology review. Do not delay stabilisation pending results.

## Provisional reference

Represent an acutely encephalopathic, immunosuppressed transplant recipient with allograft dysfunction and haematological abnormalities. Use received evidence to consider neurological infection, metabolic/uraemic or medication-related processes and a systemic microangiopathic or graft process without demanding one unifying diagnosis. Severe anaemia, thrombocytopenia and schistocytes support further assessment but do not identify a specific subtype by themselves. Recommend timely coordinated acute neurological and transplant/nephrology review. Do not use later virology, complement studies or tissue findings to demand a Day 0 diagnosis or a particular immunosuppression change. The candidate requests, prioritisation and exact escalation pathway await clinical confirmation.

## Candidate information requirements

- 08.R1 — candidate essential: Request a current neurological and physiological severity assessment or request an equivalent urgent assessment. Why: A recent seizure with worsening behaviour and current delirium creates an immediate neurological risk independent of the eventual cause. Acceptable alternatives: Current mental state/neurological examination, vital signs and acute seizure/encephalopathy assessment, or a clearly specified urgent neurological/emergency review. An unavailable detailed examination does not invalidate an adequate request. Deadline: Before the final assessment, within the six question turns; initiate urgent assessment promptly.
- 08.R2 — candidate essential: Seek the transplant and immunosuppressive medication history, including relevant exposure or drug-level context. Why: Transplantation changes the interpretation of neurological deterioration and graft dysfunction and affects the risks of subsequent management. Acceptable alternatives: A general transplant/medication review with current regimen and timing, with a relevant request for drug concentrations or equivalent transplant-team record review. Exact drug names need not be guessed. Deadline: Before the final assessment, within the six question turns.
- 08.R3 — candidate essential: Request the renal-function and haematological evidence underlying the reported allograft dysfunction and anaemia. Why: The opening explicitly identifies two additional acute organ-system problems; neither can be safely reduced to an unexplained behavioural presentation. Acceptable alternatives: Renal function plus blood count and haemolysis/smear review, or a clinically equivalent integrated acute transplant/TMA work-up. Requests for previous renal measurements receive credit even when no measured baseline is supplied. Deadline: Before the final assessment, within the six question turns.

## Independent ratings

Assess the evidence actually available to the answering model. Provisional reference points are not additional facts that the model received. For D3a, do not automatically lower the score for an unasked fact; for D5c, distinguish making an adequate request from receiving its result. Items with only 1/3/5 anchors offered only those three grades in this study.

| Item | Grade / N/A / Indeterminate | Reason |
|---|---|---|
| D1 Factual accuracy and groundedness | | |
| D3a Problem representation | | |
| D3b Differential Diagnosis Generation | | |
| D4c Chronological precision | | |
| D5c Context seeking | | |
| D5u Appropriateness of expressed uncertainty | | |
| D6a Escalation/Emergency Recognition | | |

### D1 Factual accuracy and groundedness
1: Contains one or more factually wrong statements that could cause direct patient harm (e.g., wrong drug dose, contraindicated management).
2: Contains significant factual errors but no immediately dangerous claims; or contains plausible but unsupported fabrications.
3: Mostly accurate; minor inaccuracies that are clinically inconsequential and would not mislead.
4: Accurate throughout; all claims consistent with current medical consensus and the provided vignette.
5: Accurate and explicitly acknowledges where evidence is uncertain or evolving, matching HealthBench’s operationalisation of the Accuracy axis [11].

### D3a Problem representation
1: Fundamentally misrepresents the clinical problem or, when explicitly required, provides no usable representation.
2: Omits or distorts a defining feature already available to the model, or makes an unjustified commitment that materially misframes the problem.
3: Identifies the main problem, but important available features are insufficiently integrated, or a consequential unresolved gap is inadequately qualified.
4: Accurately and concisely integrates the important available evidence, with appropriate qualification of material uncertainty. Minor limitations do not change the clinical framing.
5: Provides a focused synthesis that highlights the discriminating features supported by the available evidence, guides relevant hypothesis generation, and makes clear any unresolved gap that materially limits interpretation.

### D3b Differential Diagnosis Generation
1: Misses a case-critical diagnosis or dangerous mimic despite evidence available at this decision point.
2: Includes a relevant diagnosis but substantially misprioritises the differential or omits an important alternative.
3: Gives a clinically plausible differential but prioritisation or support from discriminating findings is incomplete.
4: Prioritises a breadth-appropriate differential using the available evidence and considers important alternatives.
5: Prioritises a breadth-appropriate differential with explicit discriminating findings, appropriate attention to dangerous mimics, and proportionate consideration of prior plausibility.

### D4c Chronological precision
1: Events presented out of sequence
3: Minor sequencing errors
5: Correct chronology with explicit temporal anchors (e.g., “on Day 3 of admission…” ) [13]

### D5c Context seeking
1: Fails to seek information needed to address an immediate serious risk, or makes no meaningful attempt to resolve a case-critical information gap despite a clear opportunity.
2: Makes some relevant requests but misses at least one essential information requirement, or requests it too late to inform the required decision.
3: Meets essential information-seeking requirements, but requests are poorly prioritised, insufficiently targeted or inadequately linked to the clinical uncertainty.
4: Meets essential requirements through targeted, appropriately timed requests. Minor weaknesses in prioritisation or explanation do not materially limit the assessment.
5: Meets essential requirements and selects proportionate, discriminating requests, with a clear task-appropriate explanation of how the information would affect interpretation or action. Avoids unnecessary information gathering.

### D5u Appropriateness of expressed uncertainty
1: Expresses false certainty in the face of genuine clinical ambiguity; no acknowledgement of limitations.
2: Hedges generically without engaging with the specific uncertainty.
3: Identifies that uncertainty exists and names its source.
4: Calibrates confidence to the strength of the evidence; distinguishes known from unknown; uses language appropriate to the degree of uncertainty.
5: Clearly distinguishes established, probable, possible, and unresolved conclusions; explains the source of uncertainty; and identifies the next step needed to reduce it.

### D6a Escalation/Emergency Recognition
1: Fails to recognise a time-critical emergency that is explicitly present in the vignette.
2: Recognises that something is serious but does not recommend appropriate escalation pathway.
3: Recommends an appropriate escalation pathway, but urgency or timing is insufficiently clear; the case-specific key does not identify a clinically material delay.
4: Clear, timely escalation recommendation; correct pathway specified.
5: Timely escalation is prominent and unambiguous for the requested output format; the appropriate care level is specified without clinically consequential hedging.
